-
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
11 Jun 2025 11:00 GMT
… Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology … AXS-12 AXS-12 (reboxetine) is a highly … Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of … ongoing clinical trials and anticipated clinical trials for the …
-
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
09 Jun 2025 11:00 GMT
… this important investigational medicine for the approximately … reboxetine. AXS-14 is an investigational drug product not approved by the FDA … portfolio includes FDA-approved treatments for major … clinical trials and anticipated clinical trials for …
-
Axsome plots new fibromyalgia trial after FDA refuses to review former Pfizer candidate
09 Jun 2025 21:05 GMT
… their primary endpoints.
Both trials were conducted by Pfizer. … the FDA’s Division of Anesthesiology, Addiction Medicine and Pain Medicine … to the New York biotech’s first quarter earnings … revitalize reboxetine, called AXS-12 at Axsome, as a treatment for …
-
Pharmacological properties of antidepressants
09 Jun 2025 00:06 GMT
Pharmacological properties of antidepressants30-49
Drug class (mode … exhaustive list)29*
Drug
Half-life
Selective … sexual dysfunction
Reboxetine
13 hrs
Tricyclic Antidepressants (TCAs)
Both … medicines.ie for more detailed information on side effects and drug …
-
Switching Antidepressants
08 Jun 2025 20:03 GMT
… guide for switching antidepressants (all antidepressant switches must be … Stop agomelatine, then start reboxetine
Stop agomelatine, then start … SPCs available on www.medicines.ie for more detailed … Fluoxetine may still cause drug interactions 5 weeks after …
-
Sleep Month in Review: June 2025
02 Jul 2025 13:45 GMT
… showcasing innovation in sleep medicine. Peter Colvonen, PhD, … data showing AXS-12 (reboxetine) significantly reduced cataplexy … trials support AXS-12’s potential as a meaningful treatment … dopamine modulator, holds FDA Orphan Drug Designation for narcolepsy. …
-
Axsome Therapeutics to present positive phase 3 results of ACCORD─2 trial of AXS─05 in AD agitation and SYMPHONY trial of AXS─12 in narcolepsy at the 2025 AAN meeting
07 Apr 2025 13:00 GMT
… pivotal SYMPHONY phase 3 trial of AXS-12 in … Medicine, New York, NY -- Session Name: Clinical Trials … treatment of Alzheimer’s disease agitation in June 2020.
AXS-12 (reboxetine … Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of …
-
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
04 Apr 2025 11:00 GMT
… antidepressant medicines called SSRIs or SNRIs. Stop taking SYMBRAVO and call your doctor … -12 AXS-12 (reboxetine) is a highly … and Drug Administration (FDA) Orphan Drug Designation for the treatment of … clinical trials and anticipated clinical trials for …
-
Experts pinpoint FIVE common medications that could raise dementia risk by up to 125%
21 Jan 2025 13:00 GMT
… diabetes medications, vitamins and supplements and antidepressants as … treatment.
Certain vaccines, antimicrobial treatments, anti-inflammatories and drugs …
'Clinical trials will help to answer …
ranitidine
rasagiline
reboxetine
rectal laxatives
renal failure …
-
Deadly side effects being 'hidden' from patients by drug firms - as scientists discover yet another harm of Ozempic
21 Jan 2025 11:00 GMT
… drugs.
The MHRA, which overseas the safety of medicines and vaccines, … all safety and trial data from pharmaceutical companies.
MPs … data that showed the antidepressant reboxetine was no more … asks doctors and pateients to report side effects of drugs, …